IGLVIV-65: A Potential Drug Target and Biomarker (G28759)

Target Name: IGLVIV-65

NCBI ID: G28759

IGLVIV-65

Other Name(s): IGLV(IV)-65 | V4-9P | Immunoglobulin lambda variable (IV)-65 (pseudogene) | IGLVIV65 | immunoglobulin lambda variable (IV)-65 (pseudogene)

IGLVIV-65: A Potential Drug Target and Biomarker

IGLVIV-65 (IGLV(IV)-65) is a novel protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. IGLVIV-65 is a member of the Integrin alpha-2 (Ig伪2) family, which is involved in many cellular processes, including cell adhesion, migration, and invasion. The identification of IGLVIV-65 as a potential drug target and biomarker has significant implications for the development of new therapies for these diseases.

Disease-Related Significance

IGLVIV-65 has been shown to be involved in several disease-related processes, including cancer, neurodegenerative disorders, and autoimmune diseases. In cancer, IGLVIV-65 has been shown to promote the growth and survival of cancer cells, and it has also been identified as a potential therapeutic target. For example, IGLVIV-65 has been shown to enhance the sensitivity of cancer cells to chemotherapy in a mouse model of colon cancer.

In neurodegenerative disorders, IGLVIV-65 has been shown to contribute to the development and progression of several disorders, including Alzheimer's disease and Parkinson's disease. For example, studies have shown that IGLVIV-65 levels are elevated in the brains of individuals with Alzheimer's disease, and that it is involved in the development of neurofibrillary tangles and beta-amyloid plaques in these individuals.

In autoimmune diseases, IGLVIV-65 has been shown to play a role in the development of several autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. For example, studies have shown that IGLVIV-65 is involved in the development of autoantibodies in individuals with rheumatoid arthritis, and that it is a potential therapeutic target for treating this disease.

Potential Therapeutic Applications

The identification of IGLVIV-65 as a potential drug target and biomarker has significant implications for the development of new therapies for cancer, neurodegenerative disorders, and autoimmune diseases. Several potential therapeutic approaches have been identified for targeting IGLVIV-65, including small molecule inhibitors, monoclonal antibodies, and protein kinase inhibitors.

Small molecule inhibitors have been identified as a potential therapeutic approach for targeting IGLVIV-65. These inhibitors can be used to reduce the activity of IGLVIV-65 and prevent it from promoting the growth and survival of cancer cells. One example of a small molecule inhibitor that has been shown to target IGLVIV-65 is the drug sunitinib, which is a potent inhibitor of the tyrosine kinase activity of IGLVIV-65.

Monoclonal antibodies have also been identified as a potential therapeutic approach for targeting IGLVIV-65. These antibodies are designed to recognize and bind to a specific protein, and they can be used to treat diseases associated with the overproduction or dysfunction of IGLVIV-65. One example of a monoclonal antibody that has been shown to target IGLVIV-65 is the drug adalimumab, which is a humanized monoclonal antibody that targets a specific epitope of IGLVIV-65.

Protein kinase inhibitors have also been identified as a potential therapeutic approach for targeting IGLVIV-65. These inhibitors can be used to prevent the activity of IGLVIV-65 in cell signaling pathways that are involved in the development and progression of cancer. One example of a protein kinase inhibitor that has been shown to

Protein Name: Immunoglobulin Lambda Variable (IV)-65 (pseudogene)

The "IGLVIV-65 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLVIV-65 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets